C Chapman1, C Thomas2, J Morling1,3,4, A Tangri5, S Oliver6, J A Simpson2, D J Humes2,3,4, A Banerjea1. 1. Eastern Hub, Bowel Cancer Screening Programme, Nottingham University Hospitals NHS Trust, Nottingham, UK. 2. Nottingham Colorectal Service, Nottingham University Hospitals NHS Trust, Nottingham, UK. 3. NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust, University of Nottingham, Nottingham, UK. 4. Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK. 5. Riverlyn Medical Centre, Nottingham, UK. 6. Nottingham City Clinical Commissioning Group, Nottingham, UK.
Abstract
AIM: We introduced primary care access to faecal immunochemical testing (FIT) as a stratification tool for symptomatic patients considered to be at risk of colorectal cancer (CRC) prior to urgent referral. We aimed to evaluate clinical and pathway outcomes during the first 6 months of this novel approach. METHOD: FIT was recommended for all patients who consulted their general practitioner with lower gastrointestinal symptoms other than rectal bleeding and rectal mass. We undertook a retrospective audit of the results of FIT, related clinical outcomes and resource utilization on prospectively logged cases between November 2017 and May 2018. RESULTS: Of the 1862 FIT kits dispatched by post 91.4% were returned, with a median return time of 7 days (range 2-110 days); however, 1.3% of returned kits could not be analysed. FIT results ≥ 150.0 μg haemoglobin (Hb)/g faeces identified patients with a significantly higher risk of CRC (30.9% vs 1.4%, chi-square 167.1, P < 0.0001). FIT results ≥ 10.0 μg Hb/g faeces identified patients with significantly higher risk of significant noncancer bowel pathology (24.1% vs 4.9%, chi-square 73.6, P < 0.0001) and FIT results < 4.0 μg Hb/g faeces identified a group more likely to have non-CRC pathology (5.1% vs 2.4%, chi-square 3.9, P < 0.05). The CRC detection rate in 531 patients investigated after a FIT result of < 4.0 μg Hb/g faeces was 0.2%. In 899 investigated patients, a FIT result with a threshold of 4.0 μg Hb/g faeces had sensitivity 97.2% (85.5-99.9% CI), specificity 61.4% (58.1-64.7% CI), negative predictive value 99.8% (98.7-100.0% CI) and positive predictive value 9.5% (8.7-10.4% CI). CONCLUSION: A symptomatic pathway incorporating FIT is feasible and appears more clinically effective than pathways based on age and symptoms alone. Colorectal Disease
AIM: We introduced primary care access to faecal immunochemical testing (FIT) as a stratification tool for symptomatic patients considered to be at risk of colorectal cancer (CRC) prior to urgent referral. We aimed to evaluate clinical and pathway outcomes during the first 6 months of this novel approach. METHOD: FIT was recommended for all patients who consulted their general practitioner with lower gastrointestinal symptoms other than rectal bleeding and rectal mass. We undertook a retrospective audit of the results of FIT, related clinical outcomes and resource utilization on prospectively logged cases between November 2017 and May 2018. RESULTS: Of the 1862 FIT kits dispatched by post 91.4% were returned, with a median return time of 7 days (range 2-110 days); however, 1.3% of returned kits could not be analysed. FIT results ≥ 150.0 μg haemoglobin (Hb)/g faeces identified patients with a significantly higher risk of CRC (30.9% vs 1.4%, chi-square 167.1, P < 0.0001). FIT results ≥ 10.0 μg Hb/g faeces identified patients with significantly higher risk of significant noncancer bowel pathology (24.1% vs 4.9%, chi-square 73.6, P < 0.0001) and FIT results < 4.0 μg Hb/g faeces identified a group more likely to have non-CRC pathology (5.1% vs 2.4%, chi-square 3.9, P < 0.05). The CRC detection rate in 531 patients investigated after a FIT result of < 4.0 μg Hb/g faeces was 0.2%. In 899 investigated patients, a FIT result with a threshold of 4.0 μg Hb/g faeces had sensitivity 97.2% (85.5-99.9% CI), specificity 61.4% (58.1-64.7% CI), negative predictive value 99.8% (98.7-100.0% CI) and positive predictive value 9.5% (8.7-10.4% CI). CONCLUSION: A symptomatic pathway incorporating FIT is feasible and appears more clinically effective than pathways based on age and symptoms alone. Colorectal Disease
Authors: Kevin J Monahan; Michael M Davies; Muti Abulafi; Ayan Banerjea; Brian D Nicholson; Ramesh Arasaradnam; Neil Barker; Sally Benton; Richard Booth; David Burling; Rachel Victoria Carten; Nigel D'Souza; James Edward East; Jos Kleijnen; Michael Machesney; Maria Pettman; Jenny Pipe; Lance Saker; Linda Sharp; James Stephenson; Robert Jc Steele Journal: Gut Date: 2022-07-12 Impact factor: 31.793
Authors: Craig Mowat; Jayne Digby; Judith A Strachan; Rebecca K McCann; Francis A Carey; Callum G Fraser; Robert Jc Steele Journal: Ann Clin Biochem Date: 2021-01-21 Impact factor: 2.057
Authors: Natalia Calanzani; Aina Chang; Marije Van Melle; Merel M Pannebakker; Garth Funston; Fiona M Walter Journal: Adv Ther Date: 2021-04-17 Impact factor: 3.845
Authors: George N Okoli; Otto L T Lam; Viraj K Reddy; Leslie Copstein; Nicole Askin; Anubha Prashad; Jennifer Stiff; Satya Rashi Khare; Robyn Leonard; Wasifa Zarin; Andrea C Tricco; Ahmed M Abou-Setta Journal: BMJ Open Date: 2021-11-09 Impact factor: 2.692
Authors: Anna Lööv; Cecilia Högberg; Mikael Lilja; Elvar Theodorsson; Per Hellström; Alexandra Metsini; Louise Olsson Journal: Diagn Progn Res Date: 2022-08-18
Authors: J A Bailey; J Weller; C J Chapman; A Ford; K Hardy; S Oliver; J R Morling; J A Simpson; D J Humes; A Banerjea Journal: BJS Open Date: 2021-03-05
Authors: Noel Pin-Vieito; Laura García Nimo; Luis Bujanda; Begona Román Alonso; María Ángeles Gutierrez-Stampa; Vanessa Aguilar-Gama; Isabel Portillo; Joaquín Cubiella Journal: United European Gastroenterol J Date: 2021-03-01 Impact factor: 4.623